Bedsted Tina, Swanson Richard, Chuang Yung-Jen, Bock Paul E, Björk Ingemar, Olson Steven T
Center for Molecular Biology of Oral Diseases, College of Dentistry, University of Illinois at Chicago, Chicago, Illinois 60612, USA.
Biochemistry. 2003 Jul 15;42(27):8143-52. doi: 10.1021/bi034363y.
Blood coagulation factor IXa has been presumed to be regulated by the serpin, antithrombin, and its polysaccharide activator, heparin, but it has not been clear whether factor IXa is inhibited by the serpin with a specificity comparable to that for thrombin and factor Xa or what determinants govern this specificity. Here we show that antithrombin is essentially unreactive with factor IXa in the absence of heparin (k(ass) approximately 10 M(-1) s(-1)) but undergoes a remarkable approximately 1 million-fold enhancement in reactivity with this proteinase to the physiologically relevant range (k(ass) approximately 10(7) M(-1) s(-1)) when activated by heparin in the presence of physiologic levels of calcium. This rate enhancement is shown to derive from three sources: (i) allosteric activation of antithrombin by a sequence-specific heparin pentasaccharide (300-500-fold), (ii) allosteric activation of factor IXa by calcium ions (4-8-fold), and (iii) heparin bridging of antithrombin and factor IXa augmented by calcium ions (130-1000-fold depending on heparin chain length). Mutagenesis of P6-P3' reactive loop residues of antithrombin further reveals that the reactivity of the unactivated inhibitor is principally determined by the P1 Arg residue, whereas exosites outside the loop which are present on the activated serpin and on heparin are responsible for heparin enhancement of this reactivity. These results together with our previous findings demonstrate that exosites are responsible for the unusual specificity of antithrombin and heparin for three clotting proteases with quite distinct substrate specificities.
血液凝固因子IXa被认为受丝氨酸蛋白酶抑制剂抗凝血酶及其多糖激活剂肝素的调节,但目前尚不清楚因子IXa是否会被该丝氨酸蛋白酶抑制剂以与凝血酶和因子Xa相当的特异性所抑制,以及哪些决定因素决定了这种特异性。在此我们表明,在没有肝素的情况下,抗凝血酶与因子IXa基本无反应(结合常数k(ass)约为10 M(-1) s(-1)),但在生理水平的钙离子存在下被肝素激活时,其与该蛋白酶的反应性会显著提高约100万倍,达到生理相关范围(k(ass)约为10(7) M(-1) s(-1))。这种反应速率的提高源于三个来源:(i)序列特异性肝素五糖对抗凝血酶的变构激活(300 - 500倍),(ii)钙离子对因子IXa的变构激活(4 - 8倍),以及(iii)钙离子增强的抗凝血酶与因子IXa之间的肝素桥连作用(根据肝素链长度不同,增强130 - 1000倍)。抗凝血酶P6 - P3'反应环残基的诱变进一步表明,未激活抑制剂的反应性主要由P1精氨酸残基决定,而激活的丝氨酸蛋白酶抑制剂和肝素上反应环外的外部位点负责肝素对这种反应性的增强作用。这些结果与我们之前的发现共同表明,外部位点决定了抗凝血酶和肝素对三种具有截然不同底物特异性的凝血蛋白酶的异常特异性。